Recent News Stay up to date on the latest news about Abpro, including press releases and upcoming publications. News Press Releases Publications Press Releases DEC 16, 2020Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19Read More → NOV 25, 2020Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease LeadersRead More → NOV 16, 2020Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against COVID-19Read More → OCT 20, 2020Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19Read More → MAR 3, 2020Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian MarketsRead More → FEB 28, 2019Abpro and NJCTTQ Enter Into Partnership For Development of Multiple Novel Bispecific AntibodiesRead More → NOV 29, 2016Medimmune and Abpro Enter into A Collaborative Agreement For a Novel Bispecific AntibodyRead More → OCT 13, 2016GEN Roundup: Immunoassays: Life Science Critical ToolsRead More → MAY 20, 2016Abpro Announces Agreements with Two Boston HospitalsRead More → APR 25, 2016Abpro Announces Investment and Partnership with Essex BioRead More → OCT 10, 2014Abpro Co-Founder Eugene Chan Wins Nokia Sensing XChallengeRead More → Publications November 6, 2019Abpro's TetraBi Platform for T-cell Engaging Antibodies targeting Claudin 18.2-expressing cancers Published for the 2019 SITC meetingRead More → MAY 16, 2019Abpro's TetraBi Platform for T-cell Engaging Antibodies Published for the 2019 ASCO MeetingRead More →
